17 December 2025   Hesperos announces the establishment of a strategic channel sales and marketing partnership with AsedaSciences, offering its pharmaceutical, cosmetic, nutraceutical and chemical industry clients a powerful combination of human-based, in silico and in vitro tools for development of safer compounds.   Traditionally, compound safety has been assessed using animal testing, but these models raise ethical concerns, lack human physiological relevance, and offer l

17 October 2025   Hesperos Inc. has been awarded  a Phase IIB SBIR grant from the National Institute on Aging to investigate the effects of medication on cognitive impairment.   In humans, drug-induced cognitive decline may arise from subtle network‑level disruption, synaptic dysfunction, neurotransmitter imbalance and moderate neuroinflammation. However, these effects are very challenging to detect using standard in vitro models and animal testing. Cognitive decline is typic

16 September 2025   Franco-American CRO Genoskin  announces it has raised  $8.7M in its first funding round led by OCCTE (FPCI Occidev Impacts) to grow its human ex vivo skin platform.   In a field that struggles to bridge the gap between preclinical promise and clinical outcome, the project carried by Genoskin has a particular significance. The development of vaccines and therapies for human skin diseases is fraught with difficulties, not least of which is the existence of n

25 September 2025   Cedars-Sinai Medical Center based in Los Angeles has been awarded $5M by Advanced Research Projects Agency for Health (ARPA-H) to develop a human-based AI-driven KronosRx platform  for improved prediction of adverse drug effects.   The ARPA-H Computational ADME-Tox and Physiology Analysis for Safer Therapeutics ( CATALYST ) program aims to revolutionize preclinical drug safety prediction by facilitating the development of next gen in vitro and in silico mo

26 September 2025   Inductive Bio , an AI drug discovery partner developing virtual chemistry labs, is awarded up to $21M by Advanced Research Projects Agency for Health (ARPA-H)  to develop AI-powered human-relevant drug toxicity prediction models. ARPA-H Computational ADME-Tox and Physiology Analysis for Safer Therapeutics  (CATALYST) program aims to revolutionize preclinical drug safety prediction by leveraging human-based models that assess safety of drug candidates more